Archive
Browse issues of the British Journal of Longevity Medicine (BJLM) by year, volume and issue. e-ISSN pending.
2027
Coming soon.
2026
Volume 1
Issue 1 Autumn–Winter 2026
Loneliness, Brain Ageing and Cognitive Healthspan: Neurobiological Mechanisms, Cognitive Consequences and Opportunities for Prevention
University of Bristol Medical School, Bristol, United Kingdom
British Journal of Longevity Medicine. 2026;1(1) · DOI pending · Published: 18 October 2026
Abstract
Loneliness is a subjective and distressing experience arising from a perceived discrepancy between desired and actual social relationships. Increasing evidence suggests that its relevance extends beyond psychological well-being to brain health, cognition and healthy ageing. This narrative review examines evidence linking loneliness with neural systems involved in social cognition, memory and stress regulation, and evaluates its association with cognitive impairment and dementia. Neuroimaging studies implicate prefrontal and default-mode networks, the hippocampal and temporal systems, anterior insula, amygdala and subcortical structures, although findings are heterogeneous and do not support a single ‘lonely brain’ phenotype. Longitudinal studies and recent meta-analyses associate persistent loneliness with poorer cognitive performance and increased risks of cognitive impairment and dementia. Potential pathways include altered social-information processing, chronic stress responses, inflammation, sleep disturbance, cerebrovascular disease, adverse health behaviours and reduced cognitive reserve. However, reverse causation and confounding by depression, sensory impairment, multimorbidity and socioeconomic factors remain important limitations. Interventions can reduce loneliness, but current evidence does not establish that doing so prevents neurodegeneration or dementia. Persistent loneliness is therefore best regarded as a potentially modifiable marker and risk factor relevant to cognitive healthspan rather than an established direct cause of neurodegeneration. Future longitudinal and interventional research should determine whether sustained reductions in loneliness translate into preservation of cognitive and brain health.
Travel Insurance, Clinical Trials and Access to Emerging Therapies
British Journal of Longevity Medicine. 2026;1(1) · DOI pending · Published: 28 October 2026
Abstract
Patients enroll in clinical trials to access novel therapies and contribute to medical progress, yet those who travel frequently still encounter unexpected barriers from travel insurers. Participation in a clinical trial is often treated as a generic red flag, with some insurers refusing cover or quoting unaffordable premiums solely on the basis of trial involvement, even when the intervention is low risk or the medicine is already approved elsewhere. Recent statements from the Association of British Insurers (ABI), supported by the Academy of Medical Royal Colleges (AoMRC) and the Health Research Authority (HRA), clarify that trial participation does not in itself imply increased risk and should not automatically lead to higher premiums or refusal of cover. However, implementation remains inconsistent and underwriting policies rarely distinguish between trial phase, intervention risk or the safety infrastructure that characterises modern UK research governance. This perspective argues that travel insurance policies must evolve in parallel with contemporary clinical trial practice, particularly as trials provide key pathways for patients to access emerging preventive and disease‑modifying therapies. We outline practical changes to underwriting frameworks, trial documentation and incident reporting that could reduce unnecessary barriers for participants, support honest disclosure and align insurance practice with evidence‑based research regulation.
